LL-37
Also known as: Cathelicidin
LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino-acid peptide (starting with two leucines) cleaved from the hCAP-18 precursor. It has broad-spectrum antimicrobial activity and immunomodulatory roles, but is also implicated in the pathogenesis of autoimmune and inflammatory skin diseases including psoriasis, rosacea, and lupus. Not FDA-approved; research-use only.
Pricing for LL-37
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for LL-37
25 third-party tests across 8 vendors. Each card links to the full report.
For
LL-37
by Verified Peptides· batch LL05260305C
For
LL-37
by Real Peptides· batch Black Cap
For
LL-37
by Ion Peptide· batch LL375-03232026
For
LL-37
by Simple Peptide· batch L1-05-01162026-J
For
LL-37
by Simple Peptide· batch LL10-37011220236-J
For
LL-37
by MedGe Peptides· batch LL375LT12
For
LL-37
by MedGe Peptides· batch LL375LT12
For
LL-37
by Simple Peptide· batch LL37L2092025-J
For
LL-37
by Real Peptides
For
LL-37
by Mile High Compounds· batch LL3-005-MH-01
For
LL-37
by BioLongevity Labs· batch 251549
For
LL-37
by Skye Peptides· batch LL25-04-002
For
LL-37
by Ion Peptide· batch LL5-1025
For
LL-37
by Simple Peptide· batch LL3708202025-J
For
LL-37
by Simple Peptide· batch LL3705072025-J
For
LL-37
by BioLongevity Labs· batch cmojb7o9z01dakirxmbk61guw
For
LL-37
by Skye Peptides· batch LL25-04-001
For
LL-37
by Verified Peptides· batch 12-24-0105A
Purity not on file
For
LL-37
by Real Peptides
Purity not on file
For
LL-37
by BioLongevity Labs· batch 16-3-45954
Purity not on file
For
LL-37
by Skye Peptides· batch LL25-04-002
Purity not on file
For
LL-37
by Skye Peptides· batch LL25-04-002
Purity not on file
For
LL-37
by Skye Peptides· batch LL25-04-001
Purity not on file
For
LL-37
by Verified Peptides· batch 12-24-0105A
31 citations indexed for LL-37
Study · 2026
Serine protease HtrA promotes <i>Campylobacter jejuni</i> intestinal colonization through degrading antimicrobial peptide LL-37
Campylobacter jejuni ( C. jejuni ) is a leading cause of human gastroenteritis worldwide and must overcome intestinal innate immunity, including antimicrobial peptide LL-37. However, how C. jejuni responds to LL-37 remains unclear. Here, we showed that C.
review · 2026
Overcoming LPS-mediated resistance in gram-negative pathogens: a review of LL-37 analogs and computational design strategies
The increasing incidence of antimicrobial resistance (AMR) in Gram-negative bacteria has become a significant global health issue, driven primarily by the structural and adaptive characteristics of lipopolysaccharide (LPS) in the outer membrane.
Study · 2026
Human cathelicidin peptide LL-37 compacts nucleic acids and alters neutrophil extracellular trap structure
The human cathelicidin host defense peptide LL-37 is expressed by many cell types, including neutrophils, macrophages, and epithelial cells, and forms complexes with nucleic acids that can have either beneficial or detrimental health effects.
review · 2026
LL-37: Biological Mechanisms and Emerging Therapeutic Applications in Intestinal Disease
Human cathelicidin peptide LL-37 is encoded by the CAMP gene and plays a key role in innate immunity. It maintains intestinal homeostasis through antibacterial, immunomodulation, and tissue repair functions.
Study · 2026
Cellulose-based hydrogel matrix enhances antimicrobial and biofilm-inhibitory responses of palatal mesenchymal stem cells
Mesenchymal stem cells (MSCs) have emerged as promising alternatives to fight drug-resistant bacterial infections.
Study · 2026
LL-37 Inhibits EV71 Infection by Upregulating STAC via the EGFR-ERK Signaling Pathway
LL-37, a 37-amino acid human-derived antimicrobial peptide, was shown in our earlier clinical study to shorten the negative conversion time of the Omicron BA.5.1.3 variant of SARS-CoV-2.